Rein Therapeutics Raises $57.5M in Fully Exercised Offering to Fund Phase 2 IPF Trial
Rein Therapeutics sold 57.5 million common shares at $1.00 each, raising gross proceeds of $57.5 million through a fully exercised over-allotment option. The company will use the net proceeds to fully fund its Phase 2 trial of LTI-03 in idiopathic pulmonary fibrosis and support operations into early 2028.
1. Public Offering Completion
Rein Therapeutics completed an underwritten offering of 57.5 million common shares at $1.00 per share, including the full exercise of a 7.5 million-share over-allotment option. The transaction generated $57.5 million in gross proceeds before underwriting discounts, with no warrants or derivative securities issued.
2. Use of Proceeds
Net proceeds will fully fund the ongoing Phase 2 RENEW trial of LTI-03 in idiopathic pulmonary fibrosis through completion, alongside manufacturing scale-up and regulatory activities. Additional funds will support general corporate and working capital requirements to sustain operations.
3. Financial Runway
Based on current plans and existing cash balances, the company expects this financing to extend its cash runway into the first quarter of 2028. This extended financial visibility underpins continued clinical development milestones for both LTI-03 and other pipeline candidates.
4. Investor Participation
The offering attracted healthcare-focused investors, including Adar1 Capital Management, Ikarian Capital, Bios Partners, Stonepine Capital, Cable Car Capital and Second Line Capital. Strong demand from both new and existing shareholders enabled the full exercise of the over-allotment option.